StrykerSYK
About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Employees: 53,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
76% more first-time investments, than exits
New positions opened: 165 | Existing positions closed: 94
70% more call options, than puts
Call options by funds: $613M | Put options by funds: $360M
28% more repeat investments, than reductions
Existing positions increased: 929 | Existing positions reduced: 728
14% more funds holding in top 10
Funds holding in top 10: 73 [Q4 2024] → 83 (+10) [Q1 2025]
1% more funds holding
Funds holding: 2,156 [Q4 2024] → 2,188 (+32) [Q1 2025]
2% more capital invested
Capital invested by funds: $108B [Q4 2024] → $110B (+$2.61B) [Q1 2025]
0.14% less ownership
Funds ownership: 77.86% [Q4 2024] → 77.72% (-0.14%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities Richard Newitter | 10%upside $415 | Hold Maintained | 4 Aug 2025 |
Wells Fargo Larry Biegelsen | 17%upside $445 | Overweight Maintained | 1 Aug 2025 |
Needham Mike Matson | 18%upside $448 | Buy Maintained | 1 Aug 2025 |
Evercore ISI Group Vijay Kumar | 10%upside $415 | Outperform Maintained | 8 Jul 2025 |
Citigroup Joanne Wuensch | 20%upside $455 | Buy Maintained | 22 May 2025 |
Financial journalist opinion
Based on 17 articles about SYK published over the past 30 days
